vs
Side-by-side financial comparison of HARROW, INC. (HROW) and Xeris Biopharma Holdings, Inc. (XERS). Click either name above to swap in a different company.
HARROW, INC. is the larger business by last-quarter revenue ($89.1M vs $85.8M, roughly 1.0× Xeris Biopharma Holdings, Inc.). Xeris Biopharma Holdings, Inc. runs the higher net margin — 12.9% vs 7.4%, a 5.5% gap on every dollar of revenue. On growth, Xeris Biopharma Holdings, Inc. posted the faster year-over-year revenue change (42.8% vs 33.3%). Over the past eight quarters, HARROW, INC.'s revenue compounded faster (60.5% CAGR vs 45.3%).
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Xeris Biopharma Holdings, Inc. is a specialty biopharmaceutical company that develops and commercializes targeted therapies for rare endocrine, metabolic, and dermatological conditions. It operates across global markets, focusing on delivering accessible, easy-to-administer treatment options for underserved patient segments.
HROW vs XERS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $89.1M | $85.8M |
| Net Profit | $6.6M | $11.1M |
| Gross Margin | 79.3% | — |
| Operating Margin | 17.5% | 19.5% |
| Net Margin | 7.4% | 12.9% |
| Revenue YoY | 33.3% | 42.8% |
| Net Profit YoY | -2.2% | 316.7% |
| EPS (diluted) | $0.20 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $89.1M | $85.8M | ||
| Q3 25 | $71.6M | $74.4M | ||
| Q2 25 | $63.7M | $71.5M | ||
| Q1 25 | $47.8M | $60.1M | ||
| Q4 24 | $66.8M | $60.1M | ||
| Q3 24 | $49.3M | $54.3M | ||
| Q2 24 | $48.9M | $48.1M | ||
| Q1 24 | $34.6M | $40.6M |
| Q4 25 | $6.6M | $11.1M | ||
| Q3 25 | $1.0M | $621.0K | ||
| Q2 25 | $5.0M | $-1.9M | ||
| Q1 25 | $-17.8M | $-9.2M | ||
| Q4 24 | $6.8M | $-5.1M | ||
| Q3 24 | $-4.2M | $-15.7M | ||
| Q2 24 | $-6.5M | $-15.0M | ||
| Q1 24 | $-13.6M | $-19.0M |
| Q4 25 | 79.3% | — | ||
| Q3 25 | 75.3% | — | ||
| Q2 25 | 74.5% | — | ||
| Q1 25 | 67.5% | — | ||
| Q4 24 | 78.8% | — | ||
| Q3 24 | 75.6% | — | ||
| Q2 24 | 74.4% | — | ||
| Q1 24 | 69.5% | — |
| Q4 25 | 17.5% | 19.5% | ||
| Q3 25 | 20.6% | 9.0% | ||
| Q2 25 | 17.9% | 6.3% | ||
| Q1 25 | -23.5% | -5.1% | ||
| Q4 24 | 19.3% | 2.8% | ||
| Q3 24 | 2.7% | -23.8% | ||
| Q2 24 | 3.1% | -17.0% | ||
| Q1 24 | -20.0% | -35.1% |
| Q4 25 | 7.4% | 12.9% | ||
| Q3 25 | 1.4% | 0.8% | ||
| Q2 25 | 7.8% | -2.7% | ||
| Q1 25 | -37.2% | -15.3% | ||
| Q4 24 | 10.1% | -8.5% | ||
| Q3 24 | -8.6% | -29.0% | ||
| Q2 24 | -13.2% | -31.2% | ||
| Q1 24 | -39.2% | -46.7% |
| Q4 25 | $0.20 | $0.07 | ||
| Q3 25 | $0.03 | $0.00 | ||
| Q2 25 | $0.13 | $-0.01 | ||
| Q1 25 | $-0.50 | $-0.06 | ||
| Q4 24 | $0.19 | $-0.02 | ||
| Q3 24 | $-0.12 | $-0.11 | ||
| Q2 24 | $-0.18 | $-0.10 | ||
| Q1 24 | $-0.38 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $111.0M |
| Total DebtLower is stronger | $250.0M | $220.3M |
| Stockholders' EquityBook value | $52.4M | $13.7M |
| Total Assets | $399.5M | $383.5M |
| Debt / EquityLower = less leverage | 4.77× | 16.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $72.9M | $111.0M | ||
| Q3 25 | $74.3M | $91.6M | ||
| Q2 25 | $53.0M | $59.3M | ||
| Q1 25 | $66.7M | $58.4M | ||
| Q4 24 | $47.2M | $71.6M | ||
| Q3 24 | $72.6M | $69.4M | ||
| Q2 24 | $71.0M | $77.6M | ||
| Q1 24 | $76.0M | $87.4M |
| Q4 25 | $250.0M | $220.3M | ||
| Q3 25 | $347.2M | $219.5M | ||
| Q2 25 | $250.6M | $218.6M | ||
| Q1 25 | $256.9M | $229.8M | ||
| Q4 24 | $262.7M | $232.1M | ||
| Q3 24 | $230.7M | $216.2M | ||
| Q2 24 | $236.3M | $230.5M | ||
| Q1 24 | $243.4M | $229.7M |
| Q4 25 | $52.4M | $13.7M | ||
| Q3 25 | $47.0M | $-861.0K | ||
| Q2 25 | $49.7M | $-19.3M | ||
| Q1 25 | $56.5M | $-35.1M | ||
| Q4 24 | $69.7M | $-29.6M | ||
| Q3 24 | $58.0M | $-28.3M | ||
| Q2 24 | $58.5M | $-19.3M | ||
| Q1 24 | $60.6M | $-9.2M |
| Q4 25 | $399.5M | $383.5M | ||
| Q3 25 | $363.1M | $370.2M | ||
| Q2 25 | $345.0M | $334.7M | ||
| Q1 25 | $364.2M | $315.5M | ||
| Q4 24 | $389.0M | $323.1M | ||
| Q3 24 | $351.5M | $321.1M | ||
| Q2 24 | $306.6M | $331.7M | ||
| Q1 24 | $295.5M | $336.6M |
| Q4 25 | 4.77× | 16.10× | ||
| Q3 25 | 7.39× | — | ||
| Q2 25 | 5.05× | — | ||
| Q1 25 | 4.55× | — | ||
| Q4 24 | 3.77× | — | ||
| Q3 24 | 3.98× | — | ||
| Q2 24 | 4.04× | — | ||
| Q1 24 | 4.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.4M | $20.0M |
| Free Cash FlowOCF − Capex | $8.1M | — |
| FCF MarginFCF / Revenue | 9.1% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | 1.27× | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | $43.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.4M | $20.0M | ||
| Q3 25 | $16.6M | $18.4M | ||
| Q2 25 | $-803.0K | $182.0K | ||
| Q1 25 | $19.7M | $-10.0M | ||
| Q4 24 | $-17.8M | $2.0M | ||
| Q3 24 | $3.0M | $-8.3M | ||
| Q2 24 | $-2.7M | $-10.3M | ||
| Q1 24 | $-4.6M | $-20.3M |
| Q4 25 | $8.1M | — | ||
| Q3 25 | $16.4M | — | ||
| Q2 25 | $-969.0K | — | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $-18.3M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $-3.1M | — | ||
| Q1 24 | $-4.7M | — |
| Q4 25 | 9.1% | — | ||
| Q3 25 | 22.9% | — | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 40.8% | — | ||
| Q4 24 | -27.4% | — | ||
| Q3 24 | 4.8% | — | ||
| Q2 24 | -6.3% | — | ||
| Q1 24 | -13.6% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 1.27× | 1.81× | ||
| Q3 25 | 16.26× | 29.68× | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.62× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HROW
Segment breakdown not available.
XERS
| Products | $83.4M | 97% |
| Other | $2.4M | 3% |
